|
15 Apr 2025 |
Healthcare Global
|
Consensus Share Price Target
|
533.90 |
526.25 |
- |
-1.43 |
buy
|
|
|
|
|
28 Feb 2025
|
Healthcare Global
|
Axis Direct
|
533.90
|
575.00
|
501.65
(6.43%)
|
7.70 |
Buy
|
|
|
We maintain our BUY recommendation on the stock.
|
|
25 Feb 2025
|
Healthcare Global
|
ICICI Securities Limited
|
533.90
|
525.00
|
515.15
(3.64%)
|
Target met |
Hold
|
|
|
HealthCare Global Enterprises’ (HCG) current promoter CVC Capital (Aseco PTE) is likely to sell up to 54% of its stake in the company to another private equity (PE) firm, KKR, at an agreed price of INR 445/share (cumulative value between INR 320bn–339bn).
|
|
11 Dec 2024
|
Healthcare Global
|
Axis Direct
|
533.90
|
575.00
|
504.45
(5.84%)
|
7.70 |
Buy
|
|
|
We recommend HCG with a BUY rating and a target price of Rs 575/share, implying a 14% upside from the CMP.
|
|
12 Nov 2024
|
Healthcare Global
|
ICICI Direct
|
533.90
|
600.00
|
467.55
(14.19%)
|
12.38 |
Buy
|
|
|
|
|
12 Nov 2024
|
Healthcare Global
|
Axis Direct
|
533.90
|
535.00
|
467.55
(14.19%)
|
Target met |
Buy
|
|
|
We maintain our BUY recommendation on the stock.
|
|
12 Aug 2024
|
Healthcare Global
|
Prabhudas Lilladhar
|
533.90
|
420.00
|
356.05
(49.95%)
|
Target met |
Buy
|
|
|
|
|
12 Aug 2024
|
Healthcare Global
|
ICICI Direct
|
533.90
|
455.00
|
356.05
(49.95%)
|
Target met |
Buy
|
|
|
|
|
09 Aug 2024
|
Healthcare Global
|
Axis Direct
|
533.90
|
395.00
|
362.25
(47.38%)
|
Target met |
Buy
|
|
|
We maintain our BUY recommendation on the stock.
|
|
28 Jun 2024
|
Healthcare Global
|
Geojit BNP Paribas
|
533.90
|
407.00
|
380.00
(40.50%)
|
Target met |
Hold
|
|
|
|
|
31 May 2024
|
Healthcare Global
|
Axis Direct
|
533.90
|
400.00
|
360.75
(48.00%)
|
Target met |
Buy
|
|
|
We maintain our BUY recommendation on the stock.
|
|
18 Mar 2024
|
Healthcare Global
|
ICICI Direct
|
533.90
|
435.00
|
342.80
(55.75%)
|
Target met |
Buy
|
|
|
|
|
12 Mar 2024
|
Healthcare Global
|
Geojit BNP Paribas
|
533.90
|
301.00
|
329.65
(61.96%)
|
|
Sell
|
|
|
|
|
12 Feb 2024
|
Healthcare Global
|
Axis Direct
|
533.90
|
410.00
|
360.30
(48.18%)
|
Target met |
Buy
|
|
|
Oncology is the fastest-growing industry in the healthcare market with a CAGR of 13.5% during FY22-FY27E. Recommendation: BUY
|
|
15 Nov 2023
|
Healthcare Global
|
Axis Direct
|
533.90
|
410.00
|
362.65
(47.22%)
|
Target met |
Buy
|
|
|
Oncology is the fastest-growing industry in the healthcare market with a CAGR of 13.5% during FY22-FY27E. We have BUY on the stock
|
|
18 Sep 2023
|
Healthcare Global
|
Geojit BNP Paribas
|
533.90
|
402.00
|
359.35
(48.57%)
|
Target met |
Accumulate
|
|
|
|
|
14 Aug 2023
|
Healthcare Global
|
ICICI Securities Limited
|
533.90
|
360.00
|
331.05
(61.27%)
|
Target met |
Accumulate
|
|
|
HCG’s Q1FY24 revenue growth of 4.3% QoQ was mainly driven by day care services. Installation of 5 LINACs (under pay for use model) led to a dip in radiation oncology services impacting revenue and gross margins. Four of the five new LINACs are operational and the management expects to restore its EBITDA margin by the end of Q4FY24, while it may add a few more LINACs in FY25.
|
|
14 Aug 2023
|
Healthcare Global
|
Axis Direct
|
533.90
|
364.00
|
331.55
(61.03%)
|
Target met |
Buy
|
|
|
Company Outlook & Guidance: Oncology is the fastest-growing industry in the healthcare market with a CAGR of 13.5% during FY22-FY27E. HCG is expected to outpace the industry growth and register a CAGR of 15% during FY23-FY26E due to its strong leadership position in the industry.
|
|
27 May 2023
|
Healthcare Global
|
Prabhudas Lilladhar
|
533.90
|
375.00
|
293.75
(81.75%)
|
Target met |
Buy
|
|
|
|
|
27 May 2023
|
Healthcare Global
|
ICICI Securities Limited
|
533.90
|
330.00
|
293.75
(81.75%)
|
Target met |
Accumulate
|
|
|
HealthCare Global Enterprises’ (HCG) Q4FY23 performance was in line with expectations. Traction was driven by mature centres though incremental revenue in new centres is not improving profitability in a meaningful way.
|
|
26 May 2023
|
Healthcare Global
|
ICICI Direct
|
533.90
|
390.00
|
293.75
(81.75%)
|
Target met |
Buy
|
|
|
|